Business Wire

Shionogi presents New Data on Cefiderocol (S-649266), a Siderophore Cephalosporin, and S-033188 a Cap-Dependent Endonuclease Inhibitor for Treatment of Influenza at ECCMID 2017

18.4.2017 05:00 | Business Wire


Shionogi & Co., Ltd. today announced it will be presenting new data on cefiderocol (S-649266), an investigational siderophore cephalosporin in late stage development with activity against a broad range of Gram-negative pathogens, including those highly resistant to currently available agents such as colistin and carbapenem-resistant strains of Pseudomonas aeruginosa, Acinetobacter baumannii, and Enterobacteriaceae (CRE) and Stenotrophomonas maltophilia, and S-033188, an investigational cap-dependent endonuclease inhibitor targeting influenza at this year’s European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), held in Vienna, Austria, April 22 – 25, 2017.

Highlights of cefiderocol presentations include first time clinical trial efficacy results, as well as supportive in vitro data, and S-033188 presentations will showcase both clinical and non-clinical data (e.g., non-clinical efficacy against avian influenza virus A/H5N1).

Below is an overview of the oral and poster presentations featuring cefiderocol and S-033188 at ECCMID 2017:

Session Title     Presentation    

Abstract Number &
Presentation Information

Late-breaker: Recent clinical trials     Cefiderocol Compared with Imipenem/Cilastatin in the Treatment of Adults with Complicated Urinary Tract Infections with or without Pyelonephritis or Acute Uncomplicated Pyelonephritis: Results from a Multicenter, Double-blind, Randomized Study (APEKS*-cUTI)    

Abstract #7582
Oral Presentation
Saturday, April 22, 2017
17:09-17:20 PM
Presenter: Simon Portsmouth

Advances in Japanese Chemotherapy     Mode of action of cefiderocol, a novel siderophore cephalosporin, active against highly resistant Gram-negative bacteria including carbapenem-resistant strains of Enterobacteriaceae and non-fermenting bacteria    

Abstract #3177
Oral Presentation
Monday, April 24, 2017
14:54-15:04 PM
Presenter: Yoshinori Yamano

Cefiderocol     In vitro activity of cefiderocol against globally collected carbapenem-resistant Gram-negative bacteria including isolates resistant to ceftazidime/avibactam, ceftolozane/tazobactam and colistin: SIDERO-CR-2014/2016 study    

Poster #1316
Poster Presentation
Monday, April 24, 2017
12:30-13:30 PM
Presenter: Yoshinori Yamano

Surveillance of cefiderocol in vitro activity against Gram-negative clinical isolates collected in Europe: SIDERO-WT-2014    

Poster #1314
Poster Presentation
Monday, April 24, 2017
12:30-13:30 PM
Presenter: Masakatsu Tsuji

    The in vitro activity of cefiderocol, a siderophore cephalosporin, against a global collection of Stenotrophomonas maltophilia    

Poster #1313
Poster Presentation
Monday, April 24, 2017
12:30-13:30 PM
Presenter: Masakatsu Tsuji

Session Title     Presentation    

Abstract Number &
Presentation Information

Advances in Japanese chemotherapy     Pharmacokinetic/pharmacodynamic analysis of S-033188, an influenza Cap-dependent endonuclease inhibitor, from a phase 2, randomized, double-blind, placebo-controlled study in otherwise healthy adults with seasonal influenza    

Abstract #1033
Oral Presentation
Monday, April 24, 2017
15:18-15:28 PM
Presenter: Takeki Uehara

Novel and improved therapeutical approaches to viral infections One day oral dosing of S-033188, a novel inhibitor of influenza virus Cap-dependent endonuclease, exhibited significant reduction of viral titer and prolonged survival in mice infected with influenza B virus    

Poster #1971
Poster Presentation
Tuesday, April 25, 2017
12:30-13:30 PM
Presenter: Takao Shishido

Pharmacokinetic and pharmacodynamic analysis of S-033188/S-033447, a novel inhibitor of influenza virus Cap-dependent endonuclease, in mice infected with influenza A virus    

Poster #1973
Poster Presentation
Tuesday, April 25, 2017
12:30-13:30 PM
Presenter: Takeshi Noshi

    Inhibitory effect of S-033188/S-033447, a novel inhibitor of influenza virus Cap-dependent endonuclease, against highly pathogenic avian influenza virus A/H5N1    

Poster #1974
Poster Presentation
Tuesday, April 25, 2017
12:30-13:30 PM
Presenter: Keiichi Taniguchi


Cefiderocol—an investigational antibiotic agent 1

Cefiderocol is a siderophore cephalosporin with a novel mechanism for efficiently penetrating the outer cell membrane of Gram-negative pathogens. Cefiderocol binds to ferric iron and is actively transported into bacterial cells through the outer membrane via the bacterial iron transporters which function to incorporate this essential nutrient for bacteria.2 This Trojan Horse strategy allows cefiderocol to achieve higher concentrations in the periplasmic space where it can then bind to receptors and inhibit cell wall synthesis in the bacterial cells.3 In addition, cefiderocol is stable against all known classes of beta-lactamases, including both the metallo- and serine-carbapenemases.4 Data from global surveillance studies for cefiderocol demonstrated potent in vitro activity against a wide spectrum of Gram-negative pathogens including carbapenem-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacteriaceae and Stenotrophomonas maltophilia. 5

About the regulatory pathway of cefiderocol

Cefiderocol is currently in clinical development and recently completed a US registrational study in patients with cUTI (APEKS*-cUTI). An additional Phase 3 trial in patients with carbapenem-resistant pathogens at various infection sites (CREDIBLE-CR) is ongoing. In 2017 Shionogi will initiate a Phase 3 HAP/VAP/HCAP† (APEKS*-NP‡) clinical trial. The Company plans to submit a new drug application to the U.S. FDA in 2017 and to the EMA in 2018. Information is available at under the identifiers NCT02321800, NCT02714595 and NCT03032380, respectively.

* Acinetobacter, Pseudomonas, Escherichia, Klebsiella and Stenotrophomonas
Hospital-Acquired Pneumonia/Ventilator-Acquired Pneumonia/Healthcare-Associated Pneumonia
Nosocomial Pneumonia

About Influenza

Epidemic and pandemic influenza remain a major public health concern, and novel influenza drugs that will offer significant improvement over current therapy are urgently needed. Worldwide, annual influenza epidemics are estimated to result in 3 to 5 million cases of severe illness, and about 250,000 to 500,000 deaths.6 In general, those at highest risk of influenza-associated complications include children under 2 years of age, adults over 65 years of age, pregnant women, and people of any age with certain medical conditions, including chronic heart, lung, metabolic diseases (such as diabetes) and weakened immune systems.

About S-033188

S-033188 is a cap-dependent endonuclease inhibitor with a novel mechanism of action being studied for the treatment of influenza. S-033188 is an investigational product being developed for one-time dosing, and has the potential to be more effective than existing marketed anti-influenza products. Development and commercialization are in collaboration with F. Hoffmann-La Roche Ltd.

About Shionogi

Shionogi & Co., Ltd. is a major research-driven pharmaceutical company dedicated to bringing benefits to patients based on its corporate philosophy of “supplying the best possible medicine to protect the health and well-being of the patients we serve.” Shionogi’s research and development currently target two therapeutic areas: infectious diseases, and pain/CNS disorders. For over 50 years, Shionogi has developed and commercialized innovative oral and parenteral anti-infectives. In addition, Shionogi is engaged in new research areas, such as obesity/geriatric metabolic disease and oncology/immunology. Contributing to the health and quality of life of patients around the world through development in these therapeutic areas is Shionogi's primary goal. For more details, please visit For more information on Shionogi Inc., the U.S.-based subsidiary of Shionogi & Co., Ltd., headquartered in Florham Park, NJ, USA, please visit For more information on Shionogi Ltd., the UK-based subsidiary of Shionogi & Co. Ltd., headquartered in London, England, please visit

Forward Looking Statement

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.




Kohira N, West J, Ito A, et al. In vitro antimicrobial activity of a siderophore cephalosporin, S-649266, against Enterobacteriaceae clinicalisolates, including carbapenem-resistant strains. Antimicrob Agents Chemother. 2015;60(2):729-734.



Ito A, Nishikawa T., Masumoto S, et al. Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2016;60(12).



Tillotson GS. Trojan Horse Antibiotics—A Novel Way to Circumvent Gram-Negative Bacterial Resistance? Infectious Diseases: Research and Treatment. 2016;9:45-52 doi:10.4137/IDRT.S31567.



Ito-Horiyama T, Ishii Y, Ito A, et al. Stability of Novel Siderophore Cephalosporin S-649266 against Clinically Relevant Carbapenemases. Antimicrob Agents Chemother. 2016;60(7):4384-4386.



M Hackel, M Tsuji, Y Yamano, et al. In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, Against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem Non-Susceptible Isolates: The SIDERO-WT-2014 Study. Antimicrobial Agents Chemotherapy (In preparation)


6. WHO website, Influenza (Seasonal), Fact sheet N°211, March 2014


Contact information

Shionogi & Co., Ltd.
Corporate Communications
Fax: +81-6-6229-9596
Investor Relations
Shionogi & Co., Ltd.
Yoshimasa Kyokawa, +81-6-6209-7885
Associate Director of Corporate Communications
Shionogi Inc. U.S. Media
Michele Mencer, +1-973-307-3353
Vice President

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Xylem joins water industry leaders and policy influencers at World Water Week 2017 to advance water and wastewater management practices24.8.2017 09:00Pressemelding

At World Water Week 2017 in Stockholm, Xylem (NYSE:XYL), a leading global water technology company, will lead and participate in forums focused on accelerating the smarter management of water and wastewater. Taking place from August 27- September 1, World Water Week will center on the theme of “Water and Waste: Reduce and Reuse” and be attended by more than 3,000 professionals from some 300 businesses, agencies and non-governmental organizations. On Sunday, August 27, Xylem is co-convening a forum entitled “Data Drought: An Assessment of Global Hydrological Monitoring Systems” along with Duke University, the Aspen Institute and the University of Oxford. This multi-stakeholder discussion will assess the severe decline in critical global water monitoring infrastructure, explore the challenges and solutions to up-scaling this infrastructure as well as the implications of non-action, and d

Announcement from SII Semiconductor Corporation: Change of Company Name24.8.2017 06:00Pressemelding

SII Semiconductor Corporation (President: Nobumasa Ishiai, Head Office: Chiba-shi, Chiba; hereinafter “SII Semiconductor”), a subsidiary of Seiko Instruments Inc. (President: Hitoshi Murakami, Head Office: Chiba-shi, Chiba; hereinafter “SII”), that manufactures and sells semiconductors today announced that the company will change its company name to ABLIC Inc. in January 5, 2018. SII Semiconductor was established in September 2015. Through a joint investment by Development Bank of Japan Inc. (President & CEO: Masanori Yanagi, Head Office: Chiyoda-ku, Tokyo; hereinafter “DBJ”) in January 2016, SII Semiconductor has deployed and expanded its business by succeeding the SII’s semiconductor business. Currently the equity of SII Semiconductor is split to 60% for SII and 40% for DBJ, but SII will transfer its 30% of the equity to DBJ and DBJ will acquire 70% after January 2018. Taking adv

Ford Names New Chairman and CEO for Ford China; New Vice President of Powertrain Engineering23.8.2017 22:00Pressemelding

Ford Motor Company today announced a new chairman and CEO of Ford China and head of Powertrain Engineering as it continues to strengthen its global leadership team. Jason Luo is named chairman and CEO Ford China. In his new role, Luo will lead all of the company’s operations in Greater China including its import business, Lincoln, its passenger car joint venture Changan Ford, commercial vehicle investment in Jiangling Motors Corporation, and our operations in Taiwan. Luo, 51, joins Ford from Key Safety Systems, the fastest growing company in the automotive safety market, where he was global president and CEO for the past 10 years. While at Key Safety Systems, he led the business transformation and global expansion of the company and achieved significant revenue growth in China. Luo will be based in Shanghai, reporting to Peter Fleet, Ford group vice preside

Tech21 Announces New Collection Designed to Protect the Samsung Galaxy Note8 Drop After Drop.23.8.2017 17:30Pressemelding

Tech21, the leader in impact protection for mobile devices, today announced a new collection of innovative cases and screen shields for the Samsung Galaxy Note8 made of unique, patented impact protection materials that guarantee the most effective drop protection on the market. This Smart News Release features multimedia. View the full release here: Evo Tactical for Samsung Galaxy Note8 (Photo: Business Wire) Tech21 products are designed to protect, drop after drop. The company does this by using scientifically proven impact materials, innovative design and a rigorous testing methodology developed in partnership with the National Physical Laboratory. Tech21 cases are drop tested 20 times to ensure durability and long lasting protection able to withstand the multiple drops that occur in the everyday

2018 AQR Insight Award Call for Papers23.8.2017 15:45Pressemelding

AQR Capital Management, LLC (“AQR”) today began accepting submissions for the seventh annual AQR Insight Award. The AQR Insight Award recognizes and rewards exceptional academic papers that have practical applications and offer original, intelligent approaches to issues in the investment world. Up to three papers share a $100,000 annual prize. Winners are chosen by the AQR Insight Award Committee, a panel of senior members of the firm, many of whom are leading academic finance experts from top universities. AQR will accept papers on any investment-related topic as long as they deliver clear, significant insights. Papers must not be published before October 1, 2017. The deadline for entries is November 1, 2017. The Committee will then narrow the finalists to five papers, and the authors of those papers will be invited to present their research to

ANA Announces New Online Content "IS JAPAN COOL? DOU"23.8.2017 15:00Pressemelding

Today, All Nippon Airways Co., Ltd. (ANA), Japan’s largest and only 5-Star airline, is proud to announce the launch of its new online content “IS JAPAN COOL? DOU,” which illustrates traditional Japanese culture through the use of cutting-edge technology. This content can be seen on “IS JAPAN COOL?,” a website that promotes tourist destinations and popular Japanese cultures to the world. This Smart News Release features multimedia. View the full release here: "IS JAPAN COOL? DOU" TOP (Graphic: Business Wire) While Japan is widely known for its unique pop culture, “IS JAPAN COOL?,” which launched in 2012, has put much of its focus on promoting Japan’s modern culture. As the number of tourists visiting Japan exceeded 24 million people as of 2016, the project aims to provide a deeper understa

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom